Skip to main content
. 2017 Nov 25;8(65):109393–109401. doi: 10.18632/oncotarget.22682

Table 1. Demographic data and clinical characteristics for each cohort.

Variable Oropharynx (n=45) % Oral (n=61) % p-value (chi Sqr) Normal (n=81) %
Age ≤60 24 (53.3%) 24 (39.3%) 0.153 64 (79.0%)
>60 21 (46.7%) 37 (60.7%) 16 (19.8%)
Gender Male 38 (84.4%) 30 (49.2%) <0.001 15 (18.5%)
Female 7 (15.6%) 31 (50.8%) 66 (81.5%)
Smoking Never 14 (31.1%) 26 (42.6%) 0.227 35 (43.2%)
Ever 31 (68.9%) 35 (57.4%) 39 (48.1%)
Alcohol Never 7 (15.6%) 15 (24.6%) 0.257 11 (13.6%)
Ever 38 (84.4%) 46 (75.4%) 62 (76.5%)
Clinical T Stage T1 5 (11.1%) 27 (45.8%) NA
T2 30 (66.7%) 19 (32.2%)
T3 5 (11.1%) 4 (6.8%)
T4 5 (11.1%) 9 (15.3%)
Clinical N Stage N0 1 (2.2%) 48 (78.7%) <0.001
N+ 44 (97.8%) 13 (21.3%)
Clinical M Stage M0 44 (97.8%) 61 (100%) 0.425*
M1 1 (2.2%) 0
Overall Clinical Stage I 0 25 (42.4%) <0.001
II 1 (2.2%) 14 (23.7%)
III 5 (11.1%) 8 (13.6%)
IV 39 (86.7%) 12 (20.3%)
Pathologic T Stage (n=47) T1 4 (36.4%) 33 (56.9%) NA
T2 7 (63.6%) 15 (25.9%)
T3 0 2 (3.4%)
T4 0 8 (13.8%)
Pathologic N Stage (n=48) N0/NX 1 (9.1%) 42 (70.0%) <0.001
N+ 10 (90.9%) 18 (30.0%)
Overall Pathologic Stage I 0 28 (48.3%) NA
II 1 (9.1%) 9 (15.5%)
III 2 (18.2%) 4 (6.9%)
IV 8 (72.7%) 17 (29.3%)
p16 Tissue negative 4 (8.9%) 59 (96.7%) <0.001
positive 41 (91.1%) 2 (3.3%)
HPV Oral rinse HPV 16 positive 33 (73.3%) * 6 (9.8%) NA 2 (2.5%)
HPV 18 positive 1 (2.2%) 0 0 (0.0%)
HR-other HPV positive alone 2 (4.4%) 2 (3.3%) 1 (1.2%)
negative 9 (20.0%) 53 (86.9%) 78 (96.3%)

Comparison of the oropharynx and oral cavity cohorts was carried out by the Chi-square test of association.

*18 of 33 were also positive for another HPV serotype.